Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
View original at globenewswire.comBiolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting –BD200 demonstrated superior uptake and cellular cytotoxicity when compared to approved drugs targeting either Trop-2 or Nectin-4…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
BD200 showed strong activity in tumor models derived from patients that were resistant to other ADCs
60% confidenceBD200 showed strong anti-tumor activity across clinically relevant human tumor models that express Trop-2 and/or Nectin-4, providing deep and durable responses
60% confidenceBD200 demonstrated superior uptake in a Trop-2/Nectin-4 dual-expressing breast cancer cell line when compared to currently marketed antibodies and antibody-drug conjugates that bind to either Trop-2 or Nectin-4 alone
60% confidenceCombined with the linker/payload we designed, BD200 has a dramatically improved therapeutic index compared to other ADCs
60% confidenceBiolojic's platform generated the first AI-designed antibody to enter the clinic, which is now in phase 2 clinical trials
60% confidenceWe're excited to share data from the first ever multibody-drug conjugate, which has the potential to transform ADC technology and, as our data suggest, lead to more efficacious and safer treatment
60% confidenceBD200 demonstrated strong anti-tumor activity in resistance settings where other antibody-drug conjugates were ineffective or had poor activity
60% confidenceBD200 demonstrated superior uptake and cellular cytotoxicity when compared to approved drugs targeting either Trop-2 or Nectin-4
60% confidenceIn mice bearing human tumors that developed resistance to other ADCs, BD200 led to deep regressions, even in larger tumors (tumor volume >2000mm3)
60% confidenceThe unique ability of a multibody to adapt to the heterogeneity of tumor antigen expression makes it an ideal base for an ADC, potentially enhancing anti-tumor activity while reducing the amount of drug needed to dose
60% confidenceBD200 demonstrated strong anti-tumor responses across patient derived xenografts of triple negative breast cancer, bladder, cervical and esophageal cancer, as well as gastric cancer in cell line-derived xenograft models
60% confidenceWe look forward to initiating our first clinical trial of BD200 later this year
60% confidenceIn cell lines resistant to ADCs that bind only to Nectin-4, switching to BD200 restored potent anti-tumor activity
60% confidence